Jean (Keyboards).Perodo: Devin Townsend (1997 - 2011) The Devin Townsend Band (2003 - 2007) Devin Townsend Project (2008 - Atual).Although not statistical significant, the incidences of PTDM and wound complications were higher in RAPA-TAC patients.
Long-term results from this study will be useful in determining the overall benefit-risk ratios from these 2 regimens. Devin Townsend Band Accelerated Evolution Rar Plus Low DoseObjective: To assess the safety and efficacy of sirolimus (SRL) plus low dose steroids as maintenance regimen with or without low dose cyclosporin (CsA) in kidney transplant recipients. Methods: We present a twelve-month interim analysis of data for this international study. All patients received CsA (125-250 ngmL) SRL (4-12 ngmL) low dose steroids daily after transplantation. At three months, eligible patients were randomized 1:1 to CsA elimination (eCsA) or minimization (mCsA). In the mCsA group, drug levels were maintained between 50-100 ngmL. In both arms, SRL trough levels were increased to achieve maintenance levels of 8-16 ngmL. Antibody induction was prohibited while steroids were generally tapered to reach 5 mg at six months. Results: Patient and graft survival at 12 months were 98.3 and 95.9 respectively (n 172). The overall first biopsy proven acute rejection rate at 12 months was 25.0 (43 episodes in 172 patients). This comprised 34 episodes (19.8) during the first 3 months of the study and 9 episodes (5.2) following randomization. Pretransplant demographic and donor variables were similar between groups. Following randomization, 4 patients experienced acute rejection in the mCsA group and 8 in the eCsA group. CsA patients had already experienced acute rejection whilst on combination treatment. All acute rejections in the post-randomisation period were mild or moderate. At twelve months, creatinine clearance was significantly higher in the eCsA group vs mCsA group; 70.9 mLmin vs 54.6 mLmin (p 0.0001). Mean serum creatinine at 12 months was significantly lower in the eCsA group vs mCsA group 124.6 v 153.4 umoll (p 0.0032). There was no significant difference in serum cholesterol, triglycerides, LDL, or HDL between the groups. Conclusions: Sirolimus permits the elimination of cyclosporin from maintenance immunotherapy and this is associated with improved renal function. Abstract 1207 PROTECTIVE EFFECTS OF SIROLIMUS ON HUMAN MESANGIAL CELL (HMC) CHOLESTEROL HOMEOSTASIS. Powis, 1 Xiong Z. Ross established the concept that atherosclerosis is an inflammatory disease (1). We have previously reported that inflammatory cytokines TNF and IL-1 increase lipid accumulation in HMCs by increasing lipid uptake through LDL receptors (2), scavenger receptors (3), and by reducing cholesterol efflux pathways via ATP binding cassette transporter A1(ABCA1). The antiproliferative properties of sirolimus have recently found clinical application in the sirolimus-eluting coronary stent (4) and a more specific antiatherosclerotic effect of sirolimus is suggested by results from the ApoE-knockout mouse model of hyperlipidaemia (5). We investigated the effect of sirolimus on cholesterol homeostasis in human mesangial cells in culture to determine possible mechanisms for an antiatherosclerotic effect. Our study demonstrated that sirolimus reduced lipid accumulation in HMCs in culture in the presence of inflammatory cytokine IL-1; shown as a reduction in Oil Red O lipid droplet staining.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |